We are live on
!
Find out more
Bellevue Group Portfolio holdings
AUM
$4.75B
Turnover
23.84%
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
(-20%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-19.85%
Top 10 Holdings %
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40
Avg Time Held
3.8
years
Top 10 Avg Time Held
2.6
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$203M |
| 2 |
Gilead Sciences
GILD
|
+$156M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$146M |
| 4 |
Amgen
AMGN
|
+$98.7M |
| 5 |
Viridian Therapeutics
VRDN
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$350M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$235M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$225M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 5 |
Amicus Therapeutics
FOLD
|
+$153M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Energy | 0.07% |
| 3 | Technology | 0.06% |
| 4 | Miscellaneous | 0.05% |
| 5 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Beta Bionics
BBNX
$934M
| $723K | 0.02% |
72,152
-133
| -0.2% | -$1.97K |
2025 Q1
4 quarters
|
|
102
Biogen
BIIB
$34.8B
| $670K | 0.02% |
3,653
+88
| +2% | +$16.2K |
2020 Q3
22 quarters
|
|
103
Legend Biotech
LEGN
$3.85B
| $649K | 0.02% |
35,886
-28,085
| -44% | -$535K |
2020 Q4
21 quarters
|
|
104
Cisco
CSCO
$433B
| $621K | 0.01% |
8,000
| – | – |
2025 Q4
1 quarter
|
|
|
105
Neurocrine Biosciences
NBIX
$13.9B
| $612K | 0.01% |
4,646
-1,698,658
| -100% | -$225M |
2016 Q1
40 quarters
|
|
106
Alibaba
BABA
$276B
| $590K | 0.01% |
4,700
| – | – |
2025 Q4
1 quarter
|
|
107
Cytokinetics
CYTK
$8.89B
| $583K | 0.01% |
8,841
-384
| -4% | -$24.4K |
2022 Q1
16 quarters
|
|
108
Certara
CERT
$1.47B
| $567K | 0.01% |
99,442
| – | – |
2023 Q3
10 quarters
|
|
109
Praxis Precision Medicines
PRAX
$6.93B
| $566K | 0.01% |
+1,757
| New | +$544K |
2026 Q1
0 quarters
|
|
110
Procter & Gamble
PG
$365B
| $563K | 0.01% |
3,900
| – | – |
2025 Q4
1 quarter
|
|
111
Mastercard
MA
$540B
| $550K | 0.01% |
1,100
| – | – |
2025 Q4
1 quarter
|
|
112
Cencora
COR
$65.2B
| $539K | 0.01% |
1,716
+1,195
| +229% | +$417K |
2022 Q1
16 quarters
|
|
113
Axsome Therapeutics
AXSM
$8.47B
| $538K | 0.01% |
3,181
-24,419
| -88% | -$4.22M |
2021 Q2
19 quarters
|
|
114
VanEck Gold Miners ETF
GDX
$26.1B
| $528K | 0.01% |
5,750
-9,750
| -63% | -$961K |
2024 Q4
5 quarters
|
|
115
AgomAb Therapeutics NV
AGMB
$410M
| $525K | 0.01% |
+50,000
| New | +$708K |
2026 Q1
0 quarters
|
|
116
Blackrock
BLK
$174B
| $433K | 0.01% |
450
| – | – |
2025 Q4
1 quarter
|
|
117
Visa
V
$750B
| $423K | 0.01% |
1,400
| – | – |
2025 Q4
1 quarter
|
|
|
CNTA
118
DELISTED
Centessa Pharmaceuticals
CNTA
| $359K | 0.01% |
+9,030
| New | +$231K |
2026 Q1
0 quarters
|
|
119
Denali Therapeutics
DNLI
$2.93B
| $341K | 0.01% |
17,766
+10,628
| +149% | +$211K |
2025 Q4
1 quarter
|
|
120
Structure Therapeutics
GPCR
$1.58B
| $328K | 0.01% |
6,803
-138,364
| -95% | -$9.47M |
2023 Q3
10 quarters
|
|
121
JD.com
JD
$37B
| $325K | 0.01% |
11,000
| – | – |
2025 Q4
1 quarter
|
|
122
Alkermes
ALKS
$6.73B
| $314K | 0.01% |
8,870
+2,276
| +35% | +$70.6K |
2025 Q3
2 quarters
|
|
123
Garmin
GRMN
$55B
| $306K | 0.01% |
1,321
-405
| -23% | -$90.7K |
2024 Q1
8 quarters
|
|
124
Summit Therapeutics
SMMT
$12.3B
| $301K | 0.01% |
15,858
+1,596
| +11% | +$25.8K |
2024 Q3
6 quarters
|
|
125
Accenture
ACN
$138B
| $297K | 0.01% |
1,500
| – | – |
2025 Q4
1 quarter
|
|
Similar funds
PTC
Bellevue Group's Q1 2026 Portfolio in Review
As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.
Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.
- Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
- Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
- Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
- Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
- Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
- Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.